CLINICAL TRIALS PROFILE FOR M.V.I.-12 LYOPHILIZED

All Clinical Trials for M.V.I.-12 LYOPHILIZED

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00024492 ↗	Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer	Completed	INSYS Therapeutics Inc	Phase 1	2001-08-01	Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids. Mitoxantrone, the active agent in the investigational formulation, is a currently marketed chemotherapeutic agent. The rationale for development of liposomal formulations is primarily that of improving the safety profile of the drug, which may permit dose intensification and/or an increase in the cumulative dose that may be administered, resulting in enhanced efficacy. LEM will be given to patients with advanced solid tumors to determine the dose of drug these patients can tolerate. Patients will receive intravenous LEM every 21 days until the disease progresses or toxicity occurs requiring treatment discontinuation. Anti-tumor effects of LEM will be assessed and patients will be evaluated for safety and tolerability.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	Massachusetts General Hospital	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.

Clinical Trial Conditions for M.V.I.-12 LYOPHILIZED

Condition Name

Condition Name for M.V.I.-12 LYOPHILIZED
Intervention	Trials
Healthy	10
Bruxism	3
Healthy Volunteer	2

Condition MeSH

Condition MeSH for M.V.I.-12 LYOPHILIZED
Intervention	Trials
Ulcer	6
Syndrome	5
Communicable Diseases	4

Clinical Trial Locations for M.V.I.-12 LYOPHILIZED

Trials by Country

Trials by Country for M.V.I.-12 LYOPHILIZED
Location	Trials
United States	118
China	12
Italy	10
Germany	8
Canada	6

Trials by US State

Trials by US State for M.V.I.-12 LYOPHILIZED
Location	Trials
Texas	14
Ohio	8
Massachusetts	7
California	7
Georgia	6

Clinical Trial Progress for M.V.I.-12 LYOPHILIZED

Clinical Trial Phase

Clinical Trial Phase for M.V.I.-12 LYOPHILIZED
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	1
PHASE2	4

Clinical Trial Status

Clinical Trial Status for M.V.I.-12 LYOPHILIZED
Clinical Trial Phase	Trials
Completed	51
Recruiting	15
Not yet recruiting	14

Clinical Trial Sponsors for M.V.I.-12 LYOPHILIZED

Sponsor Name

Sponsor Name for M.V.I.-12 LYOPHILIZED
Sponsor	Trials
The University of Texas Health Science Center, Houston	7
Ohio State University Comprehensive Cancer Center	4
Abogen Biosciences (Shanghai) Co., Ltd	4

Sponsor Type

Sponsor Type for M.V.I.-12 LYOPHILIZED
Sponsor	Trials
Other	97
Industry	59
OTHER_GOV	2

Last updated: May 1, 2026

M.V.I.-12 (Lyophilized): Clinical Trials Update, Market Analysis and Projection

No complete, reliable, citation-backed public record is available for “M.V.I.-12 LYOPHILIZED” as a defined drug candidate (including INN/USAN, developer, indication(s), mechanism, trial identifiers, or regulatory filings). Without that anchor, a compliant clinical-trials update and market projection cannot be produced.

If you want this delivered in the required format (trial registry mapping, endpoint reads, market sizing by indication, uptake curve, and patent/competition context), the drug must be identifiable via an unambiguous public identifier (e.g., INN/USAN, sponsor name, or trial registry IDs).

Key Takeaways

• “M.V.I.-12 LYOPHILIZED” is not sufficiently identifiable from public sources to support a precise clinical trials update.
• A market analysis and projection cannot be grounded in verifiable indication, target profile, trial phase, and competitor set without drug identity.

FAQs

1. What does “lyophilized” change for market projection?
2. Which registry sources are typically used for clinical-trials updates?
3. How do indications drive revenue projections for biologics and formulations?
4. What data is needed to build a forecast model (trial phase, endpoints, uptake, pricing)?
5. How are competitor landscapes assessed for the same mechanism class?

References

[1]